Status:

RECRUITING

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Lead Sponsor:

ModernaTX, Inc.

Conditions:

Propionic Acidemia

Eligibility:

All Genders

1+ years

Phase:

PHASE1

PHASE2

Brief Summary

The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT0...

Detailed Description

The study will assess long-term safety of mRNA-3927. Participants with PA who were previously enrolled and completed the end-of-treatment (EOT)/early termination (ET) visit of the mRNA-3927-P101 study...

Eligibility Criteria

Inclusion Criteria:

  • Participated in Study mRNA-3927-P101.
  • Completed the EOT/ET visit in Study mRNA-3927-P101 and enroll in this study such that the first dose in this study is planned to be within 14±3 days of the last dose of mRNA-3927 in the mRNA-3927-P101 study.

Exclusion Criteria:

  • Not expected to receive clinical benefit from continued mRNA-3927 administration, in the opinion of the Investigator.
  • Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study.
  • History of liver and/or kidney transplant.

Key Trial Info

Start Date :

November 9 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 4 2031

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT05130437

Start Date

November 9 2021

End Date

December 4 2031

Last Update

March 23 2026

Active Locations (22)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (22 locations)

1

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States, 90095

2

University of Stanford Medical Center

Palo Alto, California, United States, 94304-1503

3

University of Michigan Hospitals

Ann Arbor, Michigan, United States, 48109

4

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study | DecenTrialz